Targeted Protein Degradation Mediated by Genetically Engineered Lysosome-Targeting Exosomes
Source abstract
Abstract
Protein-degrading chimeras are superior drug modalities compared to traditional protein inhibitors because of their effective therapeutic performance. So far, various targeted protein degradation strategies, including proteolysis-targeting chimeras and lysosome-targeting chimeras, have emerged as essential technologies for tackling diseases caused by abnormal protein expression. Here, we report the development and application of lysosome-targeting exosomes (LYTEXs) for the selective degradation of membrane protein targets. LYTEXs are genetically engineered exosomes expressing multivalent single-chain fragment variables, simultaneously recognizing cell-surface lysosome-targeting and to-be-degraded protein. We show that by targeting the lysosome-directing asialoglycoprotein receptor, bispecific LYTEXs can induce lysosomal degradation of membrane-associated therapeutic targets. This strategy provides a generalizable, easy-to-prepare platform for modulating surface protein expression, with the advantage of therapeutic delivery.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Protein Degradation and Inhibitors · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Chemo/Biosensing and Chemometrics, School of Biomedical Sciences, College of Chemistry and Chemical Engineering, Hunan University, Changsha 410082, China
School of Physics and Chemistry, Hunan First Normal University, Changsha 410205, China
Funding
Scientific Research Foundation of Hunan Provincial Education Department · Science and Technology Program of Hunan Province · Science Fund for Distinguished Young Scholars of Hunan Province · National Natural Science Foundation of China
References (33)
Show source-provided references
1. 10.1038/nrd.2016.21110.1038/nrd.2016.211 ↗
2. 10.1038/s41573-021-00371-610.1038/s41573-021-00371-6 ↗
3. 10.1038/s41573-020-0078-410.1038/s41573-020-0078-4 ↗
4. 10.1126/science.126041910.1126/science.1260419 ↗
5. 10.1038/s41586-020-2545-910.1038/s41586-020-2545-9 ↗
6. 10.1016/j.ymgme.2012.07.01210.1016/j.ymgme.2012.07.012 ↗
7. 10.1038/s41589-021-00770-110.1038/s41589-021-00770-1 ↗
8. 10.1021/bi00495a00110.1021/bi00495a001 ↗
9. 10.1038/s41587-022-01456-210.1038/s41587-022-01456-2 ↗
10. 10.1021/acs.biochem.2c0031010.1021/acs.biochem.2c00310 ↗
11. 10.1021/acscentsci.1c0014610.1021/acscentsci.1c00146 ↗
12. 10.1038/s41573-023-00652-210.1038/s41573-023-00652-2 ↗
13. 10.1038/s41573-020-0090-810.1038/s41573-020-0090-8 ↗
14. 10.1002/adma.20170532810.1002/adma.201705328 ↗
15. 10.1002/anie.20221812810.1002/anie.202218128 ↗
16. 10.1002/advs.20230028810.1002/advs.202300288 ↗
17. 10.7150/thno.5257010.7150/thno.52570 ↗
18. 10.1038/s41565-021-00931-210.1038/s41565-021-00931-2 ↗
19. 10.3390/ijms2201001410.3390/ijms22010014 ↗
20. 10.1038/s41580-020-0251-y10.1038/s41580-020-0251-y ↗
21. 10.1007/s40259-020-00434-x10.1007/s40259-020-00434-x ↗
22. 10.1021/jacs.8b1004710.1021/jacs.8b10047 ↗
23. 10.1016/j.ymthe.2019.11.02010.1016/j.ymthe.2019.11.020 ↗
24. 10.21769/BioProtoc.345510.21769/BioProtoc.3455 ↗
25. 10.1089/hyb.2009.001910.1089/hyb.2009.0019 ↗
26. 10.1002/pro.51910.1002/pro.519 ↗
27. 10.1016/j.xpro.2021.10097510.1016/j.xpro.2021.100975 ↗
28. 10.1016/j.biomaterials.2021.12112910.1016/j.biomaterials.2021.121129 ↗
29. 10.1080/20013078.2017.132473010.1080/20013078.2017.1324730 ↗
30. 10.1016/j.xpro.2021.10030310.1016/j.xpro.2021.100303 ↗
31. 10.1021/acs.analchem.1c0326110.1021/acs.analchem.1c03261 ↗
32. Wu, L.; Golubovskaya, V. Pd-l1-specific antibody and anti-pd-l1-car-t cells. PCT/US2021/037573, 2021.
33. 10.1038/nature2364310.1038/nature23643 ↗